Default option nudge may boost cancer screening in High-Risk groups
NCT ID NCT07682220
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This trial tests whether presenting a cancer screening appointment as a pre-selected default option (opt-out) makes people at high risk for lung or stomach cancer more likely to accept it, compared to a standard opt-in approach. Participants complete an online questionnaire and decide about a simulated screening appointment. The study also examines how people feel about being nudged once the tactic is disclosed.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Default option nudge (behavioral intervention)
- What this could lead to
- If effective, this simple scheduling change could boost cancer screening rates in high-risk populations, potentially catching more cancers early.
- What could go wrong
- This is a simulated online study, not real screening. Real-world behavior may differ, and some people may react negatively to being nudged.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
1,200 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Jun 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 74 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * High-risk population of lung cancer or gastric cancer. * Lung cancer high-risk definition (based on the 2024 Lung Cancer Screening and Early Diagnosis and Treatment Program organized by the National Health Commission of the PRC): Age ≥50 years and pack-years of smoking ≥20, including former smoking ≥20 pack-years, but smoking cessation less than 15 years (Note: Pack-years of smoking = number of packs smoked per day × number of years smoked). * Gastric cancer high-risk definition (based on the 2024 Gastric Cancer Screening and Early Diagnosis and Treatment Program organized by the National Health Commission of the PRC): Age ≥45 years old and living in areas with a high incidence of gastric cancer (Liaoning, Fujian, Gansu, Shandong, Jiangsu). * Ability to read and comprehend simplified Chinese. * The informed consent statement was read and confirmed. Exclusion Criteria: * Reading impairment preventing independent questionnaire completion. * Failure to pass attention checks and logical consistency tests embedded within the questionnaire.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Early detection of cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University
Harbin, Heilongjiang, 150081, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which nerve block wins for lung surgery pain?
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Chemo-Immunotherapy cocktail extend life in advanced stomach cancer?
- Radiation and immunotherapy combo tested against advanced lung cancer
- Radioactive antibody aims to light up hidden solid tumors
- AI trained to tell dangerous lung nodules from harmless ones